Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis

Pediatric Blood and Cancer

Volumn 60, Issue 6, 2013, Pages

  Abraham, Allistair ^a   Alsultan, Abdulrahman ^b   Jeng, Michael ^c   Rodriguez Galindo, Carlos ^d   Campbell, Patrick K ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Clofarabine; Langerhans cell histiocytosis

Indexed keywords

CLADRIBINE; CLOFARABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; CHILD; CHILDHOOD CANCER; FEBRILE NEUTROPENIA; FOLLOW UP; HEPATOMEGALY; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; LANGERHANS CELL HISTIOCYTOSIS; LIVER FIBROSIS; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REFRACTORY PERIOD; SALVAGE THERAPY; SIDE EFFECT; TREATMENT RESPONSE;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CHILD, PRESCHOOL; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; MALE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84876438656     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24436     Document Type: Article

References (14)

1. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001; 138: 728-734.
2. Gadner H, Grois N, Potschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111: 2556-2562.
3. Minkov M, Grois N, Heitger A, et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator. Med Pediat Oncol 2002; 39: 581-585.
4. The French Langerhans' Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child 1996; 75: 17-24.
5. Weitzman S, Braier J, Donadieu J, et al. 2′-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009; 53: 1271-1276.
6. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41: 2682-2689.
7. Rodriguez-Galindo C, Jeng M, Khuu P, et al. Clofarabine in refractory Langerhans cell histiocytosis. Pediatr Blood Cancer 2008; 51: 703-706.
8. Jeha S, Kantarjian H. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther 2007; 7: 113-118.
9. Steinherz PG, Meyers PA, Steinherz LJ, et al. Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. J Pediatr Hematol Oncol 2007; 29: 656-658.
10. Ogura M, Morishima Y, Kobayashi Y, et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: Results of a Japanese phase II study. Int J Hematol 2004; 80: 267-277.
11. Yamada K, Yasui M, Sawada A, et al. Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain. Pediatr Blood Cancer 2012; 58: 300-302.
12. Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med Pediatr Oncol 2002; 38: 178-182.
13. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784-789.
14. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005; 36: 215-225.